<DOC>
	<DOCNO>NCT01378546</DOCNO>
	<brief_summary>Lambert Eaton Myasthenic Syndrome ( LEMS ) rare neurological disorder result muscle weakness limit reflex activity . More half LEMS case associate malignancy , usually small cell lung cancer , tend progress quickly case couple malignant cell . 3,4diaminopyridine ( 3,4DAP ) drug demonstrate effective treating weakness associate LEMS increase strength improve autonomic symptom LEMS patient . It currently approve FDA use United States . The investigator plan use 3,4DAP treat patient LEMS Columbia University MDA/ALS Research Center .</brief_summary>
	<brief_title>Treatment Lambert-Eaton Myasthenic Syndrome ( LEMS ) With 3 , 4 DAP</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Lambert-Eaton Myasthenic Syndrome</mesh_term>
	<mesh_term>3,4-diaminopyridine</mesh_term>
	<mesh_term>4-Aminopyridine</mesh_term>
	<criteria>Be diagnose LEMS type CMS likely respond 3 , 4DAP . If female childbearing age , negative pregnancy test , willing practice effective form birth control study . Tested find ECG prolong QTc syndrome . Agrees second ECG time peak drug effect . Has understood sign Informed Consent . Is known sensitivity 3 , 4DAP . Has history past current seizure severe asthma , epileptiform EEG . Is believe investigator unable comply protocol . Is unable give inform consent . No patient exclude base race , ethnicity , gender , HIV status</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2013</verification_date>
</DOC>